Butylphthalide's Safety and Efficacy for Improving Neurological Function Prognosis in Patients With Cardiac Arrest (BNCA Trial)

NCT06353334 · tracked via the Priya Life Science China tracker

Sponsor

Tang Ziren

Phase

Phase 4

Started

2021-09-01

Last updated

2025-02-07

Condition(s) studied

ButylphthalideCardiac ArrestNeuroprotective Drugs

Investigational drug(s) / intervention(s)

Butylphthalide and Sodium Chloride Injection →Saline Solution

Butylphthalide and Sodium Chloride Injection: All enrolled patients will undergo standard treatment as per international guidelines, concurrently receiving either NBP or placebo therapy. Patients in the experimental group will receive intravenous infusion of 100ml NBP twice daily. Each patient will receive continuous medication for 14 days.

Saline Solution: All enrolled patients will undergo standard treatment as per international guidelines, concurrently receiving either NBP or placebo therapy. Patients in the control group will receive intravenous infusion of 100ml saline solution twice daily. Each patient will receive continuous medication for 14 days.

Study summary

Butylphthalide (NBP) is a neuroprotective medication capable of ameliorating neurological dysfunction induced by ischemia, hypoxia, and reperfusion injury in the brain. However, evidence regarding the improvement of neurological function prognosis in patients with return of spontaneous circulation (ROSC) after cardiac arrest (CA) by NBP is limited. This study aims to evaluate the safety and efficacy of NBP treatment in improving the neurological function prognosis of patients with ROSC after CA.The study will be a single-center, randomized, double-blind, placebo-controlled trial. The sample size is estimated to be 100 patients. Eligible patients will be randomly allocated in a 1:1 ratio to receive either NBP or placebo treatment daily for a duration of 14 days. The initial administration of NBP or placebo treatment will commence within 6 hours after ROSC following CA. The primary outcome is the proportion of patients with Cerebral Performance Category (CPC) scores of 1-2 at 90 days after randomization in each group. The primary safety outcome is the percentage of severe adverse events occurring during the 14-day treatment period. This trial will determine the efficacy of NBP in providing neuroprotective effects for patients with ROSC after CA.

Eligibility

Sex

ALL

Min age

18 Years

Max age

80 Years

Healthy volunteers

Inclusion Criteria: 1. Age 18-80 years old. 2. GCS scores ≤8 upon admission. 3. ROSC ≥30min. 4. Signed the informed consent form. Exclusion Criteria: 1. Cardiac arrest due to irreversible causes such as trauma, poisoning, etc. 2. Cardiac arrest due to end-stage conditions such as advanced cancer. 3. Persistent cardiogenic shock that is unreversed (defined as a systolic blood pressure persistently \<90mmHg despite treatment with fluid resuscitation, vasopressor agents, and inotropic medications). 4. Presence of pre-existing cerebrovascular disease prior to cardiac arrest or confirmed intracranial hemorrhage by CT scan following admission. 5. Pre-existing CPC scores of 3-5 prior to cardiac arrest. 6. Prior use of NBP or any medication containing NBP before cardiac arrest. 7. Presence of severe hepatic or renal dysfunction before cardiac arrest (defined as ≥3× upper limit of normal alanine transaminase or ≥2× upper limit of normal creatinine). 8. Bradycardia or sick sinus syndrome occurs after ROSC. 9. History of prior drug or food allergies, or known allergies to the medication components used in this study. 10. Existence of treatment limitations (patient or their legal representative refusing advanced life support treatment, including mechanical ventilation, chest compressions, targeted temperature management, etc.). 11. Presence of severe bleeding tendency upon admission. 12. Body temperature \<30℃ upon admission. 13. Pregnant or lactating women, or reproductive-age females with elevated serum hCG levels. 14. Other conditions deemed unsuitable for this trial by the principal investigator.

Primary outcome measure(s)

The proportion of patients with a CPC score of 1-2 — 90 days
The primary outcome is the proportion of patients with a CPC score of 1-2 at 90days after randomization in each group. Favourable: 1 means full recovery or mild disability, 2 means moderate disability but independent in activities of daily living (ADLs). Unfavourable: 3 means severe disability-Dependent in ADLs, 4 means persistent vegetive state, 5 means Death.

Trial sites (1)

Facility	City	Region	Status
Beijing Chao-Yang Hospital	Beijing	Beijing Municipality	Recruiting

More Tang Ziren trials in China

Neuroprotective Effect of Butylphthalide for Cardiac Arrest Patients Recruiting

The Safety and Efficacy of Median Nerve Electrical Stimulation for Improving Neurological Function Prognosis in Patients With Cardiac Arrest Starting soon

Resting Energy Expenditure and Substrate Consumption in Cardiac Arrest Patients Under Target Temperature Management Recruiting

The Relationship Between Brain Injury Biomarkers in Cerebrospinal Fluid and Blood of Patients After Cardiac Arrest and Prognosis Recruiting

The Impact of Targeted Temperature Management Duration on Thrombin Function in Cardiac Arrest Patients Active, not recruiting

Other trials for the same condition

Target-directed Management of Cerebral Oxygenation in Patients After Receiving ECPR Recruiting

PET-CT to Assess Brain Damage in Cardiac Arrest Patients Starting soon

Neuroprotection Bundles For Comatose Survivors Following Cardiac Arrest Recruiting

Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment Starting soon

Plasma Biomarkers and Platelet Morphology of Extracorporeal CardioPulmonary Resuscitation Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06353334 on ClinicalTrials.gov ↗ ← All trials in China